gpi1 Antibody

What are the common applications for GPI antibodies in research?

GPI antibodies are primarily used in Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), and ELISA applications . These antibodies demonstrate reactivity across multiple species including human, mouse, and rat samples . The most extensively documented application is Western Blot, with at least 26 publications utilizing this method, followed by Immunofluorescence with 2 publications, and IHC with 1 documented publication as of early 2025 .

What is the molecular weight range for detecting GPI protein?

The calculated molecular weight of human GPI is 63 kDa, though the observed molecular weight typically ranges between 55-64 kDa in experimental conditions . This variation may result from post-translational modifications, alternative splicing, or differences in experimental conditions. When analyzing Western blot results, researchers should expect bands within this range rather than precisely at the calculated weight.

What are the recommended dilutions for different applications of GPI antibodies?

The optimal dilution varies by application method. Based on validated protocols:

These ranges provide starting points for optimization, but researchers should titrate the antibody in each specific testing system to obtain optimal results as signal strength can be sample-dependent .

How should antigen retrieval be performed for IHC with GPI antibodies?

For immunohistochemistry applications with GPI antibodies, the suggested antigen retrieval protocol utilizes TE buffer at pH 9.0. Alternatively, antigen retrieval may be performed with citrate buffer at pH 6.0 . The optimal method should be determined empirically for specific tissue types, as some tissues may require different conditions for maximum epitope exposure and minimum background staining.

What are the validated cell lines and tissues for GPI antibody testing?

For Western blot applications, GPI antibodies have been validated in several cell lines including HeLa cells, PC-3 cells, U251 cells, and U87-MG cells . In immunohistochemistry, these antibodies have been successfully used on human lung cancer tissue and human normal colon tissue . For immunofluorescence, PC-3 cells have shown positive results . When designing experiments, using these validated samples as positive controls can help establish assay reliability.

Why might GPI antibodies fail to recognize soluble forms of GPI-anchored proteins?

GPI-anchored proteins undergo conformational changes when delipidated (removal of the GPI anchor), which can significantly affect antibody recognition. Research on Thy-1, another GPI-anchored protein, demonstrates that many antibodies developed against membrane-bound (GPI-anchored) forms have reduced or no affinity for delipidated, soluble forms . This phenomenon occurs because delipidation induces stable conformational changes in the protein structure. For accurate detection of soluble GPI, researchers should select antibodies specifically validated for detecting the delipidated form or consider using epitope tags as an alternative detection method.

How can researchers distinguish between membrane-bound and soluble forms of GPI proteins?

Distinguishing between membrane-bound and soluble forms requires methodological consideration:

• Differential centrifugation: Use ultracentrifugation to separate membrane fragments (pellet) from truly soluble proteins (supernatant)

• Detergent phase separation: Triton X-114 phase separation can be used to separate hydrophobic (membrane-associated) from hydrophilic (truly soluble) proteins

• Enzymatic verification: Treatment with phosphatidylinositol-specific phospholipase C (PI-PLC) can release GPI-anchored proteins from membranes, creating a reference for comparison

• Immunological approach: Use antibodies that specifically recognize either the membrane-bound or soluble form, or use epitope tags for detection

These approaches should be combined for conclusive determination of protein state.

What storage conditions maximize GPI antibody stability and performance?

GPI antibodies should be stored at -20°C where they remain stable for one year after shipment. For the specific formulation mentioned in the search results, aliquoting is unnecessary for -20°C storage. The antibodies are typically provided in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . Some preparations may contain 0.1% BSA for additional stability . For long-term storage, avoid repeated freeze-thaw cycles by dividing into single-use aliquots if frequent access is needed.

How does the GPI anchor affect epitope accessibility in various detection methods?

The GPI anchor fundamentally alters protein conformation and epitope accessibility. Studies with Thy-1, another GPI-anchored protein, revealed that antibodies raised against membrane-bound forms often fail to recognize delipidated versions in immunoblotting . This phenomenon extends to many GPI-anchored proteins and occurs because the lipid anchor stabilizes specific conformational states.

For comprehensive detection strategies:

• Use multiple antibodies targeting different epitopes

• Employ epitope tags (like FLAG) inserted into recombinant constructs, which can detect the protein regardless of lipidation status

• Consider native vs. denaturing conditions in immunoassays, as some conformational epitopes may be destroyed under denaturing conditions

What are the methodological considerations for detecting GPI proteins in body fluids?

Detection of GPI proteins in body fluids presents unique challenges. Research on Thy-1 suggests that most GPI-anchored proteins detected in body fluids retain their GPI anchor and associate with membrane fragments or vesicles rather than existing as truly soluble proteins . Methodological considerations include:

• Ultracentrifugation to separate vesicle-associated from truly soluble forms

• Use of detergents to disrupt vesicle structures

• Selection of antibodies validated for the specific form (lipidated vs. delipidated)

• Consideration of exosome isolation techniques for comprehensive analysis

• Verification through mass spectrometry to confirm protein identity and modifications

Researchers should note that failure to detect GPI proteins in fluids may indicate methodological limitations rather than absence of the protein.

How can researchers validate GPI antibody specificity for immunostaining applications?

Comprehensive validation of GPI antibody specificity for immunostaining requires multiple approaches:

• Positive and negative controls: Use cell lines with known GPI expression levels (e.g., HeLa, PC-3, U251, and U87-MG cells show positive WB results )

• Peptide competition assays: Pre-incubation of the antibody with purified antigen should eliminate specific staining

• Genetic validation: Use of CRISPR/Cas9 knockout or siRNA knockdown samples as negative controls

• Cross-platform validation: Confirm staining patterns with orthogonal methods (e.g., RNA-seq, proteomics)

• Multi-antibody approach: Use multiple antibodies targeting different epitopes to verify consistent staining patterns

For advanced tissue studies, tissue microarrays containing multiple samples provide robust validation of staining patterns across diverse contexts.

What approaches can resolve data contradictions in GPI detection between different antibodies?

When different antibodies against GPI yield contradictory results, systematic troubleshooting is necessary:

• Epitope mapping: Different antibodies may recognize distinct epitopes with varying accessibility in different sample preparations

• Conformational sensitivity: Some antibodies may recognize only specific conformational states

• Protocol optimization: Each antibody may require specific conditions for optimal performance (fixation method, antigen retrieval, blocking)

• Sample preparation effects: The state of the GPI anchor significantly affects antibody recognition; delipidation can eliminate recognition by certain antibodies

• Orthogonal validation: Use non-antibody methods (mass spectrometry, RT-PCR) to verify protein presence

For definitive resolution, researchers might consider epitope tagging strategies or generating new antibodies against multiple epitopes.

How can GPI antibodies be employed in mass cytometry (CyTOF) applications?

Mass cytometry (CyTOF) with metal-labeled GPI antibodies has been successfully employed for multiplex tissue analysis. The CPTC-GPI-1 antibody demonstrated positive results in prostate cancer tissue core imaging when used at a 1:100 dilution of 0.5mg/mL stock . This technique allows visualization of GPI distribution in relation to other markers and cellular structures, with successful detection across multiple normal tissues including liver, bone marrow, spleen, placenta, prostate, colon, pancreas, breast, lung, testis, endometrium, appendix, and kidney . Researchers should optimize metal labeling efficiency and antibody concentration to achieve optimal signal-to-noise ratio for their specific tissue type.

What considerations should be made when selecting between monoclonal and polyclonal GPI antibodies?

The choice between monoclonal and polyclonal antibodies depends on research objectives:

For critical applications, validation with both types provides complementary advantages and increases confidence in results.